Weight Loss Medications See Dramatic Rise in Prescriptions Despite Limited Insurance Coverage
The demand for weight loss medications has reached unprecedented levels, with prescription fills more than doubling in 2024, according to data released by GoodRx. This surge in popularity is largely attributed to the buzz surrounding GLP-1 and GIP agonists, a class of medications that mimic gut hormones to suppress appetite and regulate blood sugar.
Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound Lead the Charge
Two of the most prominent weight loss drugs, Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, have seen prescription fills increase by over 100% and 300%, respectively, since the start of 2024. Zepbound’s remarkable growth can be attributed to its first year on the market, having received U.S. approval in November 2023. Wegovy, on the other hand, won U.S. approval in 2021.
Limited Insurance Coverage and High Out-of-Pocket Costs
Despite the significant increase in prescription fills, insurance coverage for these medications remains limited. Only 9% of people with commercial insurance have unrestricted coverage of Zepbound, while 14% have unrestricted coverage of Wegovy. Moreover, out-of-pocket costs can add up quickly, with the average insured person taking Zepbound expected to pay over $2,500 a year in copays.
Americans Overspend on Weight Loss Medications
GoodRx estimates that Americans have overspent by at least $200 million by paying full retail prices for weight loss medications instead of leveraging savings options. The company’s coupons and assistance programs offered by Eli Lilly and Novo Nordisk can help individuals save an average of $250 monthly, or $3,000 annually.
Federal Proposals Aim to Expand Access to Weight Loss Treatments
The Biden administration has proposed a rule that would allow Medicare and Medicaid to cover weight loss drugs for patients with obesity. If approved, this rule would significantly expand access to these treatments, which have been shown to have a significant impact on public health.
Leave a Reply